In an attempt to combine the effects of two severe clinical risk factors (dyslipidemia and diabetes) for renal disease, we used the hyperlipidemic diabetic apolipoprotein E-deficient (apoE−/−) mouse in our study. This evidence concerns the gene APOE and metabolic syndrome.